Filing Details
- Accession Number:
- 0001209191-19-002871
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2019-01-08 17:38:25
- Reporting Period:
- 2019-01-07
- Accepted Time:
- 2019-01-08 17:38:25
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1001233 | Sangamo Therapeutics Inc | SGMO | Biological Products, (No Disgnostic Substances) (2836) | 680359556 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1691265 | R. Edward Conner | C/O Sangamo Therapeutics, Inc. Point Richmond Tech Ctr, 501 Canal Blvd. Richmond CA 94804 | Sr. Vp & Chief Medical Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2019-01-07 | 5,000 | $3.20 | 17,125 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2019-01-07 | 5,000 | $12.33 | 12,125 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Option (Right to Buy) | Disposition | 2019-01-07 | 5,000 | $0.00 | 5,000 | $3.20 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 130,000 | 2026-11-29 | No | 4 | M | Direct |
Footnotes
- Includes 6,125 shares subject to restricted stock units granted on January 24, 2018 that will vest in three (3) equal annual installments on each anniversary of the grant date, such that they will be vested in full on the third (3rd) anniversary of the grant date, subject to the Reporting Person's continued service with the Issuer through such date.
- All sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 16, 2017.
- The price reported is a weighted average price. The shares were sold at prices ranging from $12.17 to $12.44 The Reporting Person will provide upon request to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price.
- One-quarter (1/4) of the option shares vested and became exercisable upon completion of one (1) year of service by the Reporting Person measured from the grant date, and the remainder will vest and become exercisable in equal monthly installments for thirty-six (36) months thereafter, provided that the Reporting Person remains in service with the Issuer through each such monthly vesting date.
Billionaire Hedge Funds
